The global cell-based assays market, valued at US$ 20.2 billion in 2023, is poised for significant growth, with an anticipated 6.4% CAGR from 2024 to 2034. By 2034, the market is expected to reach US$ 40.4 billion. Cell-based assays, also known as cellular assays, play a crucial role in evaluating cell health, proliferation, viability, chemotaxis, invasion, and migration. They are widely utilized in drug development and biomedical research to precisely measure off-target interactions, biochemical processes, biological activity, and cytotoxicity.
Cell-based assays offer several advantages over traditional biochemical tests. They provide more physiologically relevant data, allowing for a deeper understanding of drug properties. Additionally, they are capable of generating and facilitating complex and meaningful data, providing a more comprehensive picture of cellular processes.
The increasing use of cell-based assays is driven by their ability to enhance the drug development process. They provide essential biological data regarding drug action mechanisms, cellular survival, and off-target consequences. This allows for early identification and mitigation of any potential toxicity concerns that might arise in later stages of clinical trials.
High-throughput cell-based assay procedures are highly efficient, enabling the testing of multiple chemicals under various conditions simultaneously. This results in a large volume of data, proving particularly effective in identifying potential drug candidates early on in the drug development process. The results generated from cell-based assays are increasingly being used by academic institutions and commercial businesses to develop treatments for chronic diseases.
The market for cell-based assays is segmented based on product type, application, end user, and region. North America currently holds a significant market share and is projected to maintain its leading position throughout the forecast period. This growth can be attributed to the rising number of drug discovery research collaborations between academic institutions and pharmaceutical companies in the region. Furthermore, the increasing incidence of chronic illnesses, such as diabetes, osteoarthritis, cardiovascular disease, and cancer, particularly in the United States, is fueling the market’s expansion in North America.
The global cell-based assays market is characterized by the presence of several key players who are actively developing innovative cell-based tests to improve disease diagnosis. Some of the prominent companies operating in this market include:
* Danaher Corporation
* GE Healthcare Inc.
* Charles River Laboratories
* Lonza Group Ltd.
* Thermo Fisher Scientific Inc.
* Merck & Co.
* PerkinElmer Inc.
* Cell Signaling Technology, Inc.
* Becton, Dickinson and Company
* Promega Corporation
These companies are making significant strides in advancing the field of cell-based assays. For instance, Beckman Coulter Life Sciences unveiled the Aquios STEM system in May 2022, a revolutionary approach to stem cell analysis. This system aims to significantly reduce turnaround time by eliminating manual and error-prone procedures. In June 2020, PhenoVista Biosciences and Olympus collaborated to provide 3D cell-based testing services, supporting drug discovery efforts. Promega Corporation and FUJIFILM Cellular Dynamics teamed up in March 2022 to develop novel assays for cellular biology observation, creating a system that more closely mimics the behavior of real body cells. Selvita launched a cell-based phenotypic screening tool for drug discovery in February 2021. This platform allows for the evaluation of new chemicals for potential medicinal applications.
The global cell-based assays market is experiencing significant growth, driven by its ability to accelerate drug discovery and contribute to the development of new treatments for chronic diseases. As research and development in this area continues to advance, the market is expected to witness further innovation and expansion in the coming years.
